Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia

被引：20
|
作者：
Sahin, Ilyas [1 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 12期
关键词：
D O I：
10.1056/NEJMc1809507
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1186 / 1186
页数：1
相关论文
共 50 条
  • [1] Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
    Montesinos, Pau
    Recher, Christian
    Vives, Susana
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Daigle, Scott R.
    Hui, Jianan
    Pandya, Shuchi S.
    Gianolio, Diego A.
    de Botton, Stephane
    Dohner, Hartmut
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (16): : 1519 - 1531
  • [2] Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
    Yue, Zenglian
    Pan, Chaohsuan
    Wang, Siyuan
    Tse, Archie N.
    Sheng, Yucheng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (01) : 105 - 113
  • [3] Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
    Zenglian Yue
    Chaohsuan Pan
    Siyuan Wang
    Archie N. Tse
    Yucheng Sheng
    European Journal of Clinical Pharmacology, 2024, 80 : 105 - 113
  • [4] Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Takahashi, Katsuhiko
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (08) : 864 - 866
  • [5] Servier receives Positive CHMP Opinion for Ivosidenib in Patients With IDH1-Mutated Acute Myeloid Leukemia and Bile Duct Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (05)
  • [6] Ivosidenib and Azacitidine in IDH1-Mutated AML REPLY
    Montesinos, Pau
    de Botton, Stephane
    Doehner, Hartmut
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (26): : 2536 - 2537
  • [7] Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
    Fathi, Amir T.
    Kim, Haesook T.
    Soiffer, Robert J.
    Levis, Mark J.
    Li, Shuli
    Kim, Annette S.
    DeFilipp, Zachariah
    El-Jawahri, Areej
    McAfee, Steve L.
    Brunner, Andrew M.
    Amrein, Philip C.
    Mims, Alice S.
    Knight, Laura W.
    Kelley, Devon
    Bottoms, Aj S.
    Perry, Lindsey H.
    Wahl, Jonathan L.
    Brock, Jennifer
    Breton, Elayne
    Marchione, Dylan M.
    Ho, Vincent T.
    Chen, Yi-Bin
    CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2034 - 2042
  • [8] A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
    Lachowiez, Curtis A.
    Loghavi, Sanam
    Zeng, Zhihong
    Tanaka, Tomoyuki
    Kim, Yi June
    Uryu, Hidetaka
    Turkalj, Sven
    Jakobsen, Niels Asger
    Luskin, Marlise R.
    Duose, Dzifa Y.
    Tidwell, Rebecca S. S.
    Short, Nicholas J.
    Borthakur, Gautam
    Kadia, Tapan M.
    Masarova, Lucia
    Tippett, George D.
    Bose, Prithviraj
    Jabbour, Elias J.
    Ravandi, Farhad
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Garcia, Jacqueline S.
    Vyas, Paresh
    Takahashi, Koichi
    Konopleva, Marina
    DiNardo, Courtney D.
    BLOOD CANCER DISCOVERY, 2023, 4 (04): : 276 - 293
  • [9] Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions
    Lavacchi, Daniele
    Caliman, Enrico
    Rossi, Gemma
    Buttitta, Eleonora
    Botteri, Cristina
    Fancelli, Sara
    Pellegrini, Elisa
    Roviello, Giandomenico
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    PHARMACOLOGY & THERAPEUTICS, 2022, 237
  • [10] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
    DiNardo, C. D.
    Stein, E. M.
    de Botton, S.
    Roboz, G. J.
    Altman, J. K.
    Mims, A. S.
    Swords, R.
    Collins, R. H.
    Mannis, G. N.
    Pollyea, D. A.
    Donnellan, W.
    Fathi, A. T.
    Pigneux, A.
    Erba, H. P.
    Prince, G. T.
    Stein, A. S.
    Uy, G. L.
    Foran, J. M.
    Traer, E.
    Stuart, R. K.
    Arellano, M. L.
    Slack, J. L.
    Sekeres, M. A.
    Willekens, C.
    Choe, S.
    Wang, H.
    Zhang, V.
    Yen, K. E.
    Kapsalis, S. M.
    Yang, H.
    Dai, D.
    Fan, B.
    Goldwasser, M.
    Liu, H.
    Agresta, S.
    Wu, B.
    Attar, E. C.
    Tallman, M. S.
    Stone, R. M.
    Kantarjian, H. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25): : 2386 - 2398
12345